Abstract:INTRODUCTION Five-alpha reductase (5-AR) deficiency was first identified by Imperato-McGinley and Walsh as the cause of pseudohermaphroditism in two separate studies. The discoveries led to the development of finasteride (inhibitor of type 2 isoenzyme of 5-AR) and dutasteride (inhibitor of type 1 and type 2 isoenzymes of 5-AR. Both drugs have been proven effective for the treatment of benign prostatic hyperplasia and improve voiding symptoms, reduce the risk of urinary retention and the need for prostate surgery. Five-alpha reductase inhibitors 5-ARIs have been demonstrated to be chemopreventive agents and reduce the risk of prostate cancer, although the risk of selecting out or mediating higher grade prostate cancer remains uncertain. A lower dose of finasteride has been shown to be effective in the treatment of male pattern baldness. Materials and methods: A Medline search was performed using mesh terms, benign prostatic hypertrophy, prostate cancer, male pattern baldness, female and 5-AR. Results: The Prostate Long Term Efficacy and Safety Study (PLESS) was a randomized double-blind study that established that finasteride resulted in a 22% increase in maximum flow rate and a 19% decrease in prostate volume. Further studies demonstrated that finasteride caused a significant reduction in the risk of the need for surgery and urinary retention in a 4 year period. Additional studies showed similar beneficial results with dutasteride. The potential benefits of 5-ARIs as chemopreventive agents were examined in the Prostate Cancer Prevention Trial (PCPT) and the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) studies. In the 7 year PCPT trial, 18.4% of the finasteride group developed prostate cancer compared to 24.4% in the placebo group. In the 4 year REDUCE trial, there was a 22.8% reduction of prostate cancer at the conclusion of the study. Despite the reduction of prostate cancer in both the PCPT and REDUCE trials, each study showed an increased risk of prostate cancer in the treatment arms. The explanation for these observations remains an area of investigation. Low dose finasteride has also been used successfully for the treatment of male pattern baldness. Conclusions: The use of 5-ARIs has been a major advance in urologic clinical practice. Urologists should be familiar with the underlying pharmacology of 5-ARIs as well as the clinical indications for their use.

The Role of 5α-Reductase in Prostate Disease and Male Pattern Baldness

Serum Levels of Androgen-Associated Hormones Are Correlated with Curative Effect in Androgenic Alopecia in Young Men

Selective non-steroidal inhibitors of 5 alpha-reductase type 1

The clinical applications of five-alpha reductase inhibitors

Androgen physiology and the cutaneous pilosebaceous unit

Progress in the Study of 5Α-Reductases Used As A Target in Natural Medicine Screening

A Review of the Azasteroid-type 5-alpha Reductase Inhibitors for the Management of Benign Prostatic Hyperplasia

Androgen Receptor Expression in Male Pattern Baldness Patients

[Natural 5Α-Reductase Inhibitors in Treatment of Benign Prostatic Hyperplasia].

[Role of 5 Alpha-Reductase Inhibitors in the Chemoprevention of Prostate Cancer].

[Expression and Significance of Steroid 5Alpha-Reductase Isoenzymes in Benign Hyperplastic Prostate Tissues].

Role of 5α-reductase Inhibitors in the Chemoprevention of Prostate Cancer

Abstract A105: Androgen Regulation of 5Α-Reductase Isoenzymes in Prostate Cancer: Implications for Prostate Cancer Prevention

Immunolocalization of 5alpha-reductase isozymes in acne lesions and normal skin

Glucocorticoids are induced while dihydrotestosterone levels are suppressed in 5-alpha reductase inhibitor treated human benign prostate hyperplasia patients

New 5alpha-reductase inhibitors: in vitro and in vivo effects

Identification of Beta-Sitosterol and Stigmasterol as Possible Inhibitors of 5 Alpha-Reductase 1: An In-Silico Study

Structure of human steroid 5α-reductase 2 with the anti-androgen drug finasteride

The role of the androgen receptor in prostate development and benign prostatic hyperplasia: A review

Finasteride Inhibits 5 Alpha-Reductase Activity in Human Dermal Fibroblasts: Prediction of Its Therapeutic Application in Androgen-Related Skin Diseases.

The extract of Thujae occidentalis semen inhibited 5alpha-reductase and androchronogenetic alopecia of B6CBAF1/j hybrid mouse